VistaGen Therapeutics公司:Fasedienol在主要及次要终点上未实现统计学显著改善

美股速递
Jun 30

VistaGen Therapeutics, Inc. (VTGN) 近日公布,其候选药物Fasedienol在关键临床试验中,未能于主要及次要疗效终点上展现出统计学意义上的显著改善。这一结果标志着该药物在特定治疗路径上遭遇了重大挫折,引发了市场对公司研发管线进展的重新评估。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10